NDA 218197 · Astrazeneca
Truqap
Capivasertib · Oral
NovelPriority reviewCDER novel approval, Nov 16, 2023: To treat breast cancer that meets certain disease criteria
Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Nov 16, 2023
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
65
11 Phase 3, 17 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: To treat breast cancer that meets certain disease criteria
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Capivasertib" as an intervention, any sponsor and status, largest first.
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02465060 · 6,452 participants (planned) · Start Aug 17, 2015 · Primary completion Dec 31, 2027
Drug: Adavosertib; Afatinib and 30 more · For: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma and 49 more
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 1,410 sites in all
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerPivotal-lookingActive, not recruiting
UNICANCERAcademic, hospital or other
NCT02299999 · 1,460 participants · Start Apr 7, 2014 · Primary completion Dec 2022
Drug: AZD2014; AZD4547 and 17 more · For: Metastatic Breast Cancer
Sites: Angers, France; Avignon, France; Bordeaux, France · 25 sites in all
- The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) TrialStatus unknown
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT03182634 · 1,150 participants (planned) · Start Dec 15, 2016 · Primary completion Nov 2022
Drug: Fulvestrant; Neratinib and 3 more · For: Advanced Breast Cancer
Sites: Sutton, United Kingdom; Bournemouth, United Kingdom; Bristol, United Kingdom · 19 sites in all
- Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA TestingPivotal-lookingNot yet recruiting
SWOG Cancer Research NetworkResearch network
NCT07802626 · 1,084 participants (planned) · Start Oct 30, 2026 · Primary completion Oct 30, 2034
Drug: NSAI + CDK4/6i; NSAI + CDK4/6i + Capivasertib and 2 more · For: HR Positive/HER-2 Negative Breast Cancer
- Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05348577 · 1,035 participants · Start Mar 25, 2022 · Primary completion Mar 4, 2026
Drug: capivasertib; docetaxel · For: Prostate Cancer
Sites: Yuma, Arizona; Beverly Hills, California; Cerritos, California · 217 sites in all
- Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN DeficiencyPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT04493853 · 1,012 participants · Start Jul 13, 2020 · Primary completion Oct 7, 2024
Drug: Capivasertib; Abiraterone Acetate · For: Hormone-Sensitive Prostate Cancer
Sites: Tucson, Arizona; La Jolla, California; Orange, California · 323 sites in all
- SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC PatientsPivotal-lookingCompleted
UNICANCERAcademic, hospital or other
NCT02117167 · 999 participants · Start Apr 23, 2014 · Primary completion Dec 22, 2018
Drug: AZD2014; AZD4547 and 9 more · For: Non-small Cell Lung Cancer Metastatic
Sites: Avignon, France; Besançon, France; Bobigny, France · 37 sites in all
- Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBCPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT03997123 · 923 participants · Start Jun 25, 2019 · Primary completion Mar 16, 2026
Drug: Capivasertib; Paclitaxel and 1 more · For: Triple Negative Breast Neoplasms
Sites: Whittier, California; Fort Myers, Florida; Miami, Florida · 260 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Truqap (Capivasertib)
2024 spending
$184M
Beneficiaries
2,247
8,670 claims
Per beneficiary
$81,962
$349.43 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $1,501,470 |
| 2024 | $184,169,026 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Turner NC, Oliveira M, Howell SJ, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Randomized Controlled Trial
- Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study.
Fizazi K, Clarke NW, De Santis M, et al. · Ann Oncol 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
- Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.
Oliveira M, Rugo HS, Howell SJ, et al. · Lancet Oncol 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study.
Rugo HS, Oliveira M, Howell SJ, et al. · ESMO Open 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Systematic Review and Network Meta-Analysis on Treating Hormone Receptor-Positive Metastatic Breast Cancer After CDK4/6 Inhibitors.
Pathak N, Mittal A, Kumar S, et al. · Curr Oncol 2025 · Network Meta-Analysis, Systematic Review
- Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort.
Hu X, Zhang Q, Sun T, et al. · Nat Commun 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.